PUBLISHER: The Business Research Company | PRODUCT CODE: 2036077
PUBLISHER: The Business Research Company | PRODUCT CODE: 2036077
Rare disease registries are structured databases that systematically collect and maintain information on patients with rare medical conditions. They allow longitudinal monitoring of disease progression, treatment outcomes, and epidemiological trends. These registries support research, clinical decision-making, and therapeutic development by providing consistent, reliable patient data.
The key types of rare disease registries include product registries, health services registries, and disease registries. Product registries are organized databases tracking patient outcomes and safety information for specific therapies or interventions. Database types include population-based and hospital-based, with software options including standalone and integrated solutions. Functions include data collection, data analysis, patient recruitment, and others, serving pharmaceutical companies, research organizations, hospitals, government agencies, and other end-users.
Tariffs have influenced the rare disease registries market by increasing the costs of importing advanced registry software, data management tools, and analytic platforms. This impact is most notable in segments such as software and integrated registry solutions, particularly in regions like North America and Europe with high reliance on imported technologies. While tariffs may slow adoption and increase operational costs, they also encourage local development of registry solutions, fostering innovation, cost optimization, and resilience in the market.
The rare disease registries market research report is one of a series of new reports from The Business Research Company that provides rare disease registries market statistics, including rare disease registries industry global market size, regional shares, competitors with a rare disease registries market share, detailed rare disease registries market segments, market trends and opportunities, and any further data you may need to thrive in the rare disease registries industry. This rare disease registries market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The rare disease registries market size has grown rapidly in recent years. It will grow from $1.62 billion in 2025 to $1.82 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising awareness of rare diseases, increasing clinical research activities, growth in hospital and population-based registries, regulatory support for patient data collection, limited availability of structured patient data.
The rare disease registries market size is expected to see rapid growth in the next few years. It will grow to $2.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to adoption of ai-driven registry solutions, integration with genomic and omics data, expansion of personalized medicine initiatives, investment in cloud-based interoperable platforms, enhanced patient engagement and data sharing. Major trends in the forecast period include real-time patient data collection, integration with electronic health records (ehr), advanced data analytics for rare diseases, patient recruitment and retention optimization, interoperable registry platforms.
The growing government initiatives and funding support are expected to fuel the expansion of the rare disease registries market over the forecast period. Government initiatives and funding support include public programs and financial investments aimed at strengthening healthcare infrastructure, encouraging innovation, and improving service delivery. Rising public funding reflects efforts to enhance data-driven policymaking, optimize resource allocation, and improve outcomes for underserved patient populations, including individuals with rare diseases. Rare disease registries are pivotal in achieving these objectives by aggregating comprehensive patient data that guide policy decisions, enable targeted funding allocation, and support the design and evaluation of effective healthcare and research programs. For instance, in February 2025, the UK government's central executive authority committed around £26 billion ($35 billion) over two years to support the health and care system, emphasizing investment in data infrastructure and population health initiatives. Therefore, growing government initiatives and funding support are driving the growth of the rare disease registries market.
Key companies operating in the rare disease registries market are focusing on developing advanced products such as, an AI-enabled patient registry infrastructure to enhance real-time data capture, patient monitoring, and research insights across rare diseases. AI-enabled patient registry infrastructure refers to registry systems that leverage artificial intelligence to process, analyze, and interpret large-scale patient and clinical data efficiently, enabling predictive analytics, natural history modeling, and real-world evidence generation. For example, in May 2024, National Organization for Rare Disorders (NORD), a US-based non-profit advocacy organization dedicated to individuals with rare diseases and the organizations that serve them, launched the first Canadian rare disease patient registries on its IAMRARE platform for phenylketonuria (PKU) and mucopolysaccharidoses (MPS), allowing real-time cooperative data collection, supporting multiple languages and regional consent requirements, and providing valuable insights for clinical trial eligibility, disease progression tracking, and treatment evaluation.
In October 2023, IQVIA Holdings Inc., a US-based provider of healthcare data, analytics, and technology solutions, acquired Open Applications Consulting Limited (OpenApp) for an undisclosed amount. Through this acquisition, IQVIA enhanced its capabilities in patient registry software and real-world evidence solutions, improving its ability to build, deploy, and scale disease-specific registries by integrating OpenApp's customizable registry platforms to support longitudinal data capture, research insights, and clinical program needs across rare and chronic conditions. Open Applications Consulting Limited (OpenApp) is an Ireland-based health technology company developing patient registry and health intelligence software used to collect and manage disease-specific clinical and real-world data, including platforms for rare disease and low-prevalence condition registries.
Major companies operating in the rare disease registries market are disease registries market are Deloitte Touche Tohmatsu Limited, International Business Machines Corporation, Oracle Corporation, BC Platforms Ltd., IQVIA Holdings Inc., ICON plc, Veeva Systems Inc., Alira Health Inc., Phastar Ltd., HealthVerity Inc., OM1 Inc., Synapse Laboratory, Castor EDC, RedCap Cloud, Within3 Inc., Sage Bionetworks, National Organization for Rare Disorders Inc., RTI Health Solutions, ArborMetrix Inc., Evado Clinical Systems Ltd., ClinCapture LLC, Global Vision Technologies Inc., Genetic Alliance UK, Pulse Infoframe.
North America was the largest region in the rare disease registries market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease registries market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the rare disease registries market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rare disease registries market includes revenues earned by entities through epidemiological tracking, outcomes monitoring, and data quality assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rare Disease Registries Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses rare disease registries market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for rare disease registries ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare disease registries market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.